

ATTORNEY DOCKET NO. P51271

Form PTO-1595

U.S. DEPARTMENT OF COMMERCE
Patent and Trademark OfficeRECORDATION FORM COVER SHEET
PATENTS ONLY**CERTIFICATION OF FACSIMILE TRANSMISSION**I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office
Assignment Branch at (703) 306-5995 on December 2, 2003 byMaureen StumpoMaureen Stumpo

Commissioner of Patents. Please record the attached original documents or copy thereof.

1. Name of conveying party(ies) Dashyant DHANAK Timothy F. GALLAGHER Steven D. KNIGHT and Stanley J. SCHMIDT		2. Name and address of receiving party(ies) SmithKline Beecham Corporation One Franklin Plaza 200 North 16th Street Philadelphia, PA 19103 United States of America	
Additional names of conveying party(ies) attached? <input type="checkbox"/> yes <input checked="" type="checkbox"/> no		Additional name(s) and addresses attached? <input type="checkbox"/> yes <input checked="" type="checkbox"/> no	
3. Description of the interest conveyed: <input checked="" type="checkbox"/> Assignment, please record and return <input type="checkbox"/> Merger <input type="checkbox"/> Security Agreement <input type="checkbox"/> Change of Name <input type="checkbox"/> Other			
Execution date of Assignment: May 20, 28, 29 and 30, 2002			
4. Application number(s) or patent number(s). Additional Sheets attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No			
A. Patent Application No.(s) SERIAL NO. 10/477,053, FILED NOVEMBER 7, 2003		B. Patent No.(s)	
If this document is being filed together with a new application, the execution date of the application is			
5. Name and address of party to whom correspondence concerning documents should be mailed: Linda E. Hall GlaxoSmithKline Corporate Intellectual Property - UW2220 P.O. Box 1539 King of Prussia, PA 19406-0939		6. Total number of applications and patents involved <u>1</u> .	
		7. Total Fee (37 C.F.R. 3.41) <u>\$40.00</u>	
		8. Please charge this fee to deposit account No. <u>19-2570</u> .	
The Commissioner is hereby authorized to charge any additional fees under 37 CFR 1.16 or 1.17 which may be required by this paper, or credit any overpayment, to our Deposit Account No. 19-2570.			
DO NOT USE THIS SPACE			
9. Statement and Signature. <i>To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.</i>			
<u>Linda E. Hall</u> Name of Person Signing		<u>Linda E Hall</u> Signature	
		<u>December 2, 2003</u> Date	
Total number of pages including cover sheet, attachments and document: 4			

n:\eh\cases\p51271\record\assignment.doc

CH \$40.00 192570 10477053

Docket No.: P51271

ASSIGNMENT

WHEREAS we, Dashyant DHANAK of King of Prussia, Pennsylvania 19406, a citizen of United Kingdom; Timothy F. GALLAGHER of Collegeville, Pennsylvania 19426, a citizen of United States of America; and Steven D. KNIGHT of King of Prussia, Pennsylvania 19406, a citizen of United States of America; and Stanley J. SCHMIDT of King of Prussia, Pennsylvania 19406, a citizen of United States of America; have made an invention entitled:

"SULFONAMIDES"

for which on an even date we executed an application for Letters Patent of the United States under 35 U.S.C. §111(a), executed an application for Letters Patents of the United States under 35 U.S.C. §371, or filed a Provisional application under 35 U.S.C. §111(b):

NOW, THEREFORE, in return for valuable consideration paid to us by SmithKline Beecham Corporation, a corporation organized under the laws of the Commonwealth of Pennsylvania and having its principal place of business at One Franklin Plaza, 200 North 16th Street, Philadelphia, Pennsylvania 19103, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound, we do hereby assign unto the said SmithKline Beecham Corporation, its successors and assigns, the entire right, title and interest in and to the said invention, executed under 35 U.S.C. §111(a), 35 U.S.C. §371, or filed under 35 U.S.C. §111(b) application, and from which priority may be claimed from one or more 35 U.S.C. §111(b) applications, or any division, continuation and continuation-in-part of said application, and all Letters Patent of the United States and all foreign countries to be obtained therefor;

We further assign to the said SmithKline Beecham Corporation the right, optionally in its own name or in the names of its related companies, to apply for, obtain and maintain in all countries foreign to the United States, patent and/or Utility Model applications for said invention, including the full right to claim for any such application the benefits of any priority rights based on said executed United States application;

And we agree to execute further instruments (including provisional, divisional, continuation, continuation-in-part or reissue applications or other instruments) proper to effectuate the premises, this agreement to be binding upon our heirs, executors and administrators;

And we request the Commissioner of Patents and Trademarks of the United States, and any official of any country or countries foreign to the United States whose duty it is to issue patents on applications as aforesaid, to issue Letters Patent in accordance herewith.

